PAPER Gillette-Guyonnet S, Secher M, Vellas B

Nutrition and neurodegeneration: epidemiological evidence and challenges for future research.

Br J Clin Pharmacol. 2013 Mar;75(3):738-55. PubMed: 23384081

PAPER Valera E, Masliah E

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies.

Pharmacol Ther. 2013 Jun;138(3):311-22. PubMed: 23384597

PAPER González-Palau F, Franco M, Jiménez F, Parra E, Bernate M, Solis A

Clinical utility of the hopkins verbal test-revised for detecting Alzheimer's disease and mild cognitive impairment in spanish population.

Arch Clin Neuropsychol. 2013 May;28(3):245-53. PubMed: 23384601

PAPER Golanska E, Sieruta M, Gresner SM, Pfeffer A, Chodakowska-Zebrowska M, Sobow TM, Klich I, Mossakowska M, Szybinska A, Barcikowska M, Liberski PP

APBB2 genetic polymorphisms are associated with severe cognitive impairment in centenarians.

Exp Gerontol. 2013 Apr;48(4):391-4. PubMed: 23384821

PAPER Wozniak MA, Itzhaki RF

Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1.

J Neuroimmunol. 2013 Apr 15;257(1-2):7-12. PubMed: 23385080

PAPER Collin F, Sasaki I, Eury H, Faller P, Hureau C

Pt(II) compounds interplay with Cu(II) and Zn(II) coordination to the amyloid-β peptide has metal specific consequences on deleterious processes associated to Alzheimer's disease.

Chem Commun (Camb). 2013 Mar 14;49(21):2130-2. PubMed: 23386213

PAPER Alper BJ, Schmidt WK

Evaluating amyloid Beta (aβ) 1-40 degradation by capillary electrophoresis.

Methods Mol Biol. 2013;984:263-73. PubMed: 23386350

PAPER Christa Maree Stephan B, Minett T, Pagett E, Siervo M, Brayne C, McKeith IG

Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review.

BMJ Open. 2013;3(2) PubMed: 23386579

PAPER Gillespie P, O'Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A,

The effects of dependence and function on costs of care for Alzheimer's disease and mild cognitive impairment in Ireland.

Int J Geriatr Psychiatry. 2013 Mar;28(3):256-64. PubMed: 23386588

PAPER Zhang YY, Fan YC, Wang M, Wang D, Li XH

Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.

Clin Interv Aging. 2013;8:103-10. PubMed: 23386786

PAPER Festa EK, Ott BR, Manning KJ, Davis JD, Heindel WC

Effect of cognitive status on self-regulatory driving behavior in older adults: an assessment of naturalistic driving using in-car video recordings.

J Geriatr Psychiatry Neurol. 2013 Mar;26(1):10-8. PubMed: 23385363

PAPER de Bruijn RF, Schrijvers EM, de Groot KA, Witteman JC, Hofman A, Franco OH, Koudstaal PJ, Ikram MA

The association between physical activity and dementia in an elderly population: the Rotterdam Study.

Eur J Epidemiol. 2013 Mar;28(3):277-83. PubMed: 23385659

PAPER Rushworth JV, Griffiths HH, Watt NT, Hooper NM

Prion Protein-mediated Toxicity of Amyloid-β Oligomers Requires Lipid Rafts and the Transmembrane LRP1.

J Biol Chem. 2013 Mar 29;288(13):8935-51. PubMed: 23386614

Željko Svedruzic on Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor

COMMENT To understand why semagacestat and avagacestat failed, we need to understand the molecular properties of those compounds. Enzymatic mechanism studies offer insights into why those compounds can facilitate cognitive decline, and why current drug developmen

Who Will Progress to AD? Brain Microstructure Offers Clues

RESEARCH NEWS 2013-02-07 Research News Subtle alterations in the brain may help predict if people with mild cognitive impairment (MCI) will progress to Alzheimer’s disease (AD), according to a small study published in the January 30 Journal of Neuroscience. Using diffusion magnet